Elanco Animal Health (NYSE:ELAN) Rating Reiterated by Stifel Nicolaus

Elanco Animal Health (NYSE:ELAN)‘s stock had its “buy” rating reaffirmed by investment analysts at Stifel Nicolaus in a note issued to investors on Thursday, Benzinga reports. They presently have a $20.00 target price on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 42.15% from the company’s previous close.

A number of other analysts have also issued reports on ELAN. Piper Sandler cut their target price on Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a research report on Monday, July 1st. Barclays cut their target price on Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating on the stock in a research report on Friday, June 28th. Finally, Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $17.00 to $15.00 in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Hold” and an average target price of $17.29.

Elanco Animal Health Stock Down 6.6 %

ELAN stock opened at $14.07 on Thursday. The firm has a market cap of $6.95 billion, a PE ratio of -5.31, a PEG ratio of 1.44 and a beta of 1.40. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.75 and a current ratio of 2.93. The firm’s 50 day moving average price is $13.95 and its 200-day moving average price is $15.17. Elanco Animal Health has a one year low of $8.52 and a one year high of $18.80.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.24 by $0.06. The firm had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.15 billion. Elanco Animal Health had a negative net margin of 27.94% and a positive return on equity of 7.29%. The business’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.18 EPS. On average, equities research analysts anticipate that Elanco Animal Health will post 0.91 EPS for the current year.

Insider Transactions at Elanco Animal Health

In related news, CEO Jeffrey N. Simmons acquired 100,000 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were acquired at an average price of $13.01 per share, with a total value of $1,301,000.00. Following the completion of the transaction, the chief executive officer now owns 145,000 shares of the company’s stock, valued at $1,886,450. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Elanco Animal Health news, CEO Jeffrey N. Simmons bought 100,000 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average price of $13.01 per share, for a total transaction of $1,301,000.00. Following the completion of the purchase, the chief executive officer now directly owns 145,000 shares in the company, valued at $1,886,450. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael J. Harrington purchased 3,500 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was acquired at an average cost of $14.85 per share, with a total value of $51,975.00. Following the completion of the acquisition, the director now directly owns 81,094 shares of the company’s stock, valued at $1,204,245.90. The disclosure for this purchase can be found here. Corporate insiders own 0.57% of the company’s stock.

Institutional Investors Weigh In On Elanco Animal Health

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Benjamin F. Edwards & Company Inc. increased its position in shares of Elanco Animal Health by 337.7% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock worth $26,000 after purchasing an additional 1,361 shares in the last quarter. ORG Partners LLC purchased a new position in Elanco Animal Health during the 2nd quarter worth approximately $31,000. nVerses Capital LLC purchased a new stake in Elanco Animal Health in the second quarter valued at approximately $32,000. Jones Financial Companies Lllp acquired a new stake in shares of Elanco Animal Health in the fourth quarter valued at approximately $37,000. Finally, Quarry LP purchased a new position in shares of Elanco Animal Health during the second quarter worth approximately $40,000. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.